Table 5.

The impact of gender, age, treatment regimen and SLC19A1 haplotypes on the occurrence of any and specific (thrombocytopenia, mucositis, and neurotoxicity) MTX-induced adverse events

	All		Thrombocytopenia		Mucositis		Neurotoxicity
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Gender	2.385	0.078	1.615	0.413	1.523	0.520	0.531	0.475
	(0.908–6.259)		(5.134–5.076)		(0.423–5.472)		(0.093–3.024)
Age	1.028	0.588	9.526	0.440	1.054	0.396	1.088	0.289
	(0.931–1.134)		(8.422–1.078)		(0.935–1.190)		(0.931–1.272)
Treatment regimen	2.050	0.031*	9.839	0.962	1.676	0.255	1.282	0.678
	(1.065–3.943)		(4.620–2.095)		(0.689–4.075)		(0.397–4.139)
H1 = CACCCCG	1.000	0.943	6.615	0.352	0.419	0.096	0.309	0.120
	(0.472–2.117)		(2.769–1.579)		(0.150–1.167)		(0.070–1.364)
H3 = TGTTGTC	1.110	0.844	9.220	0.891	0.593	0.515	0.951	0.934
	(0.335–3.618)		(2.254–3.750)		(0.122–2.877)		(0.175–5.150)
H4 = TGTTCCC	0.143	0.030*	3.617	0.379	0.005	0.985	0.014	0.992
	(0.023–0.852)		(4.568–2.541)		(0.0–NC)		(0.0–NC)
Rare haplotypes	2.002	0.275	9.113	0.871	2.002	0.275	2.002	0.275
	(0.580–6.775)		(2.607–3.171)		(0.580–6.775)		(0.580–6.775)

^*p < 0.05; H2 was the reference haplotype